KALV — Kalvista Pharmaceuticals Inc
NASDAQ · Biotechnology · Biotechnology
- Latest Close
- $19.43
- 30-Day Move
- +14.9%
- Market Cap
- $1.0B
- Shares Outstanding
- 50,550,000
- P/B Ratio
- 7.18
- ROE
- -61.3%
Analyst consensus: Buy · 15 analysts
Kalvista Pharmaceuticals Inc
A read-only Alphactor snapshot forKalvista Pharmaceuticals Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$19.43
30-Day Move
+14.9%
Market Cap
$1.0B
Shares Outstanding
50,550,000
P/B Ratio
7.18
ROE
-61.3%
$19.43
+14.9%last 90 delayed daily bars
90D High
$21.30
90D Low
$14.22
Avg Volume
1,058,484
Gross margin is running at 93.7%, which gives a quick read on operating quality before you open the full model.
Net margin is -119.2%, useful for comparing KALV against peers in Biotechnology.
KALV is up 14.9% over the last 30 trading days shown on this page.
Latest Close
$19.43
30-Day Move
+14.9%
Market Cap
$1.0B
Shares Outstanding
50,550,000
P/B Ratio
7.18
ROE
-61.3%
ROA
-32.7%
Gross Margin
93.7%
Operating Margin
-123.5%
Net Margin
-119.2%
Debt / Equity
1.11
Current Ratio
5.58
Revenue
--
Gross Profit
--
Operating Income
--
Net Income
--
Gross Margin
9372.0%
Net Margin
-11917.0%
Current Ratio
5.58
Debt / Equity
1.11
Altman Z
--
N/A
Piotroski
0
Insufficient data
Cash Conversion
--
Rule of 40
--
Insufficient data
Buy Value
$0
Sell Value
$5M
Buys
0
Sells
29
Buy Value
$0
Sell Value
$5M
Buy/Sell Ratio
0.00x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-17 | Audhya Paul K. | Sell | 2,686 | $20.22 |
| 2026-04-17 | Sweeny Nicole | Sell | 1,862 | $20.22 |
| 2026-04-17 | Piekos Brian | Sell | 1,862 | $20.22 |
| 2026-04-17 | Palleiko Benjamin L | Sell | 9,550 | $20.22 |
| 2026-04-16 | Audhya Paul K. | M | 6,250 | $0.00 |
| 2026-04-16 | Audhya Paul K. | M | 6,250 | $0.00 |
| 2026-04-16 | Sweeny Nicole | M | 6,250 | $0.00 |
| 2026-04-16 | Sweeny Nicole | M | 6,250 | $0.00 |
Qube Research & Technologies
Filed 2025-05-15
--
--
D.E. Shaw
Filed 2026-02-17
--
--
Two Sigma Advisers
Filed 2025-05-15
--
--
Vanguard Group
Filed 2026-01-29
$41M
+0.3%
BlackRock
Filed 2024-08-13
$35M
--
Geode Capital Management
Filed 2026-02-09
$15M
+1.7%
Goldman Sachs
Filed 2026-02-10
$13M
-53.6%
4.33
Consensus
Buy—
—
—
15
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.